Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Exagamglogene Autotemcel→

Exagamglogene Autotemcel PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
Not available
Molecular formula
Not available
Molecular weight
Not available
Drug class
CRISPR/Cas9 gene-edited autologous CD34+ haematopoietic stem-cell therapy
Mechanism of action
Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.
Indications / reported uses
  • Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
  • Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations

Sources: US DailyMed — CASGEVY (exagamglogene autotemcel) · US FDA prescribing information · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

CRISPR/Cas9 gene-edited autologous CD34+ haematopoietic stem-cell therapy

Mechanism of action

Autologous CD34+ cells are edited ex vivo at the erythroid-specific enhancer of BCL11A, reducing BCL11A expression in erythroid cells and increasing fetal haemoglobin (HbF) production after engraftment.

General use cases

  • Treatment of sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises, under the product-specific eligibility criteria
  • Treatment of transfusion-dependent beta-thalassaemia in patients aged 12 years and older under the applicable US and EU product authorisations

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Exagamglogene Autotemcel PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Exagamglogene Autotemcel Permitted Daily Exposure (PDE) report (the Exagamglogene Autotemcel PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Exagamglogene Autotemcel Occupational Exposure Limit (OEL) report (the Exagamglogene Autotemcel OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.